GlobeNewswire by notified

Huhtamaki steps up production of advanced smooth molded fiber packaging in Europe to provide plastic free packaging solutions

Share

HUHTAMÄKI OYJ PRESS RELEASE 24.3.2022 AT 10:00 EET

Huhtamaki steps up production of advanced smooth molded fiber packaging in Europe to provide plastic free packaging solutions

Huhtamaki, a key global provider of sustainable packaging solutions, has strengthened its manufacturing capabilities in smooth molder fiber, a transformative and technologically advanced material which can be used to produce high-precision food packaging and replace rigid plastics.

The company’s site in Alf, Germany is switching its focus from plastics to smooth molded fiber (SMF) products to meet the growing demand for plastic free alternatives for food packaging. In 2022, the unit plans to replace more than 2.000 tonnes of plastic with fiber. Huhtamaki’s state-of-the-art automated manufacturing site will have the capacity to manufacture up to 3.5 billion fiber products annually. This represents the first such large scale production capability in Europe.

Huhtamaki’s smooth molded fiber products are already in use by some of the world’s leading food service operators. The advanced manufacturing facility at Alf currently delivers fiber lids for a variety of uses and bespoke products for leading food service and FMCG brands, including an assortment of hot, cold and frozen applications. In contrast to polypropylene products made from fossil-fuels, smooth molded fiber products are renewable, compostable and can be recycled. They are a fully sustainable alternative to similar plastic products. In addition, the wood fiber used to produce Huhtamaki’s bespoke and also generic designs is sourced from certified sustainably managed European forests. The products made in Alf have been certified for home composting (“OK” certification) and industrial composting (EN13432 standards).

"There is a growing demand for sustainable alternatives to plastic packaging for food. Our high precision advanced manufacturing technology enables us to produce fiber lids, trays and other products with superior performance. These products dramatically reduce the consumption of plastic – which is mostly fossil fuel based – whilst continuing to provide the same functionality including hygiene and safety which consumers expect. Our portfolio of fiber products manufactured in Germany and our expertise in material and manufacturing innovation presents a wide range of sustainable packaging products to help customers deliver on their sustainability agenda and goals”, says Eric Le Lay, President of Huhtamaki’s Fiber Foodservice Europe-Asia-Oceania business segment.

Huhtamaki is on a journey to becoming the first choice in sustainable packaging solutions with a focus to ensure our products are recyclable, compostable, or reusable by 2030. By creating scalable and viable alternatives for plastic substitution, Huhtamaki is delivering credible sustainable food packaging options to customers, in line with its 2030 Strategy.

For further information, please contact:
Arto Gröndahl, Media Relations Manager, tel. +358 10 686 7107, media@huhtamaki.com

HUHTAMÄKI OYJ
Global Communications

About Huhtamaki
Huhtamaki is a key global provider of sustainable packaging solutions for consumers around the world, enabling wellbeing and convenience. Our innovative products protect on-the-go and on-the-shelf food and beverages, ensuring hygiene and safety, and help prevent food waste. We embed sustainability in everything we do. We are committed to achieving carbon neutral production and designing all our products to be recyclable, compostable or reusable by 2030.

We are a participant in the UN Global Compact and EcoVadis has awarded Huhtamaki with the Gold medal for performance in sustainability. To play our part in managing climate change, we have set science-based targets that have been approved and validated by the Science Based Targets initiative.

With 100 years of history and a strong Nordic heritage we operate in 38 countries and 114 operating locations around the world. Our values Care Dare Deliver guide our decisions and help our team of 19,600 employees make a difference where it matters. Our 2021 net sales totaled EUR 3.6 billion. Huhtamaki Group is headquartered in Espoo, Finland and our parent company, Huhtamäki Oyj, is listed on Nasdaq Helsinki Ltd. Find out more about how we are protecting food, people and the planet at www.huhtamaki.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding

Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis18.5.2022 15:00:00 CEST | Press release

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of tasquinimod in this patient population.” The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives. In February 2022, Active Biotech entered into an exclusive lice

Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 202218.5.2022 14:00:00 CEST | Pressemelding

2022-05-18 PRESSRELEASE Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 2022 Idag, den 18 maj 2022, hölls årsstämma i Arcoma Aktiebolag. Årsstämman genomfördes enbart genom förhandsröstning (poströstning) med stöd av tillfälliga lagregler. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat i enlighet med styrelsens förslag i årsredovisningens förvaltningsberättelse, innebärande att ingen vinstutdelning lämnas för 2021 samt att disponibla medel balanseras i ny räkning. Ansvarsfrihet åt styrelseledamöterna och verkställande direktören Årsstämman beslutade att bevilja styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2021. Val och arvodering av styrelse och

Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM18.5.2022 13:11:14 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 May 2022 Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM Björn Wahlroos, Chair of Sampo plc’s Board of Directors, has announced today that he will not be available for re-election to the Board of Directors at the Annual General Meeting to be held in spring 2023. Sampo’s Nomination and Remuneration Committee will communicate on succession in due course. SAMPO PLC For further information, please contact: Sami Taipalus Head of Investor Relations tel. +358 10 516 0030 Distribution: Nasdaq Helsinki London Stock Exchange The principal media Financial Supervisory Authority www.sampo.com

Decisions of Sampo plc’s Annual General Meeting18.5.2022 13:05:00 CEST | Press release

SAMPO PLC DECISIONS OF GENERAL MEETING 18 May 2022 at 2:05 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 18 May 2022, decided to distribute a dividend of EUR 4.10 per share for 2021. The record date for dividend payment is 20 May 2022 and the dividend will be paid on 31 May 2022. The Annual General Meeting adopted the financial accounts for 2021 and discharged the Board of Directors and the CEO from liability for the financial year. The Annual General Meeting increased the number of the members of the Board of Directors to nine members. Christian Clausen, Fiona Clutterbuck, Georg Ehrnrooth, Jannica Fagerholm, Johanna Lamminen, Risto Murto, Markus Rauramo and Björn Wahlroos were re-elected to the Board. Steve Langan was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting. At its organisational meeting, the Board elected Björn Wahlro